Navigation Links
AstraZeneca Initiates Phase 3 Clinical Trial For Selumetinib In Non-Small Cell Lung Cancer
Date:10/22/2013

BOULDER, Colo., Oct. 22, 2013 /PRNewswire/ -- AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer (NSCLC) whose tumors are KRAS mutation-positive.  

(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)

Array BioPharma (NASDAQ:   ARRY) invented and licensed worldwide rights to develop and commercialize selumetinib to AstraZeneca in 2003.  The initiation of the Phase 3 trial triggered a $5 million milestone payment to Array.  Array retains significant economic rights to selumetinib under the agreement with AstraZeneca, including double digit royalties on global commercial sales and the potential for approximately $70 million in additional milestone payments. 

Ron Squarer, Chief Executive Officer, Array BioPharma noted, "The initiation of the Phase 3 SELECT-1 trial highlights AstraZeneca's on-going commitment to develop selumetinib broadly in areas of high unmet need.  Together with the active pivotal trial in thyroid cancer and the announced uveal melanoma trial, there are already three paths to market for selumetinib."

The SELumetinib Evaluation as Combination Therapy-1 (SELECT-1) study is a randomized, double-blind, placebo-controlled study that will evaluate the safety and efficacy of selumetinib plus docetaxel as a second line therapy in locally advanced or metastatic KRAS mutation-positive NSCLC.  The study is designed to evaluate Progression Free Survival (PFS) as the primary endpoint and Overall Survival (OS) as a secondary endpoint. AstraZeneca has reported that SELECT-1 will include 220 centers globally and enroll 634 patients, who will be randomized in a rati
'/>"/>

SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
2. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
3. Omthera Stockholders Approve Acquisition by AstraZeneca
4. AstraZeneca Neuroscience partners with ePharmaSolutions to optimize Clinical Trial Management
5. Isis Pharmaceuticals Earns $6 Million Payment from AstraZeneca
6. Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
7. AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
8. AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation
9. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
10. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
11. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014   Unique ... Groups Inc.: OTC Pink: UPZS), a Delaware Corporation, ... distribution agreement with Larasan Pharmaceutical Corporation ("Larasan"), a nature-based ... According to the agreement, US-based Larasan will work ... 6" frozen pizza through Larasan,s vast distribution network ...
(Date:7/30/2014)... SANTA CLARA, Calif. , July 30, 2014 /PRNewswire/ ... innovation economy, released a study today that ... venture-backed biopharma and medical device companies.  According to the ... healthcare saw the biggest potential returns since SVB started ... the year of the IPO.  Built on solid healthcare ...
(Date:7/30/2014)... 30, 2014  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: ... on its expertise in opioid antagonists, announced today ... a prominent international research and development foundation. ... innovative research-based initiatives, including those addressing health issues. ... the delivery of naloxone that could widely expand ...
Breaking Medicine Technology:Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3
... This is your last week to pre-register for MD&M ... of Suppliers ,   Educational Opportunities ... all in   One Convenient Location.     ... at   http://www.MDMEast.com . Medical ...
... May 18, 2012 /PRNewswire-iReach/ -- Denton Vacuum ... today launched a new website that guides ... "The site,s organization and navigation mirror what it,s like ... and understands your business and technical drivers," says Rod ...
Cached Medicine Technology:Medical Device Developers - Network at MD&M East Next Week 2Medical Device Developers - Network at MD&M East Next Week 3Denton Vacuum's New Website Organizes Thin-Film Technology Information By Industry 2
(Date:7/30/2014)... 30, 2014 2014 Deep ... Industry” is a professional and in-depth research ... report provides basic Chitosan information, including Chitosan ... as well as industry overview. This research ... market as well as global industry analysis ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The report ... Others), by Application (Healthcare, Food, Water Treatment, Pulp & ... & ROW) - Global Trends & Forecasts to 2018". ... size of 229.54 kilotons by 2019, signifying a robust ... study. , Browse 83 market data tables and 33 ...
(Date:7/30/2014)... By Amy Norton ... -- Spending time in a garden might help soothe the ... suggests. Looking at 17 past studies, British researchers found ... garden can help soothe some dementia patients, anxiety. The ... patients are a tough subject to study -- and the ...
(Date:7/30/2014)... Of the many sub-groups of cells jockeying for supremacy ... be those that can proliferate the fastest, researchers at ... an advance online publication of the journal Nature ... treatment of cancer with precision medicines, the study authors ... truly driving the tumor,s growth and metastasis and select ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 According ... and Machine Vision Market by Technology (ICS, MES, ... Embedded), Components (Camera, FGOL), Application (Process, Discrete) - ... published by MarketsandMarkets, the Mexican market is expected ... 6.18% by 2020. , Browse 70 market data ...
Breaking Medicine News(10 mins):Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 2Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 3Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 4Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 2Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 3Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 4Health News:Gardens a Center of Calm for People With Dementia 2Health News:Gardens a Center of Calm for People With Dementia 3Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 4
... tool powered by SNAPforSeniors(R) helps members quickly,locate safe housing, ... rash of tornadoes in more than 20 years destroyed ... Tennessee Tuesday night., Emergency warnings gave most residents ... housing, natural disasters bring extra fears. Lack,of mobility, limited ...
... safety review , , FRIDAY, Feb. 8 (HealthDay News) -- ... and severe side effects for others treated for a ... related products. , Most of the children were being ... caused by cerebral palsy, the U.S. Food and Drug ...
... patients (both children and adults) when given gadolinium ... pre-medicated with corticosteroids and antihistamines, according to a ... of Michigan Health Systems in Ann Arbor. ... who have a history of prior allergic-like reaction ...
... Technologically advanced program provides new treatment options for ... patients and physicians throughout the region, WAUKESHA, Wis., Feb. ... opening of its new Center for Advanced Wound,Healing. The hospital ... interested in touring the facility on Wednesday, February 13,from 4:00 ...
... The Integrated,Healthcare Association (IHA) welcomes Leah Binder, ... National Pay for Performance Summit at the,Beverly Hilton ... the,leading forum on pay for performance to enhance ... has made outstanding contributions toward the,improvement of healthcare ...
... the only one if its kind in the Pacific ... Care Alliance (SCCA),and Northwest Hospital & Medical Center today ... the development of a new, state-of-the-art,cancer treatment facility offering ... intention to develop a proton-therapy,facility in September 2006 and ...
Cached Medicine News:Health News:Tennessee Tornadoes Spur Senior Move Managers to Aid Elderly in Crisis 2Health News:Tennessee Tornadoes Spur Senior Move Managers to Aid Elderly in Crisis 3Health News:FDA Warns of Children's Deaths Linked to Botox 2Health News:FDA Warns of Children's Deaths Linked to Botox 3Health News:Allergic-like reactions occur in premedicated patients 2Health News:LifeCare Hospitals of Wisconsin Unveils Center for Advanced Wound Healing 2Health News:Integrated Healthcare Association Welcomes Leah Binder, New CEO of Leapfrog Group to National Pay for Performance Summit 2Health News:Seattle Cancer Care Alliance and Northwest Hospital Sign Letter of Intent to Develop Proton Therapy Center for Cancer Treatment 2Health News:Seattle Cancer Care Alliance and Northwest Hospital Sign Letter of Intent to Develop Proton Therapy Center for Cancer Treatment 3
The OX-2 is configured asstandalone or handheld unit, designed for hospital, transport and home use....
Rad-9™...
... 8600 Series Tabletop/Portable Digital Pulse ... tool for patient monitering. From ... the 8600 has earned the ... and is recognized for its ...
... Medicals ONE™ technology is the ... uses a patented digital sensor ... an analog sensor. Dolphin ONE™ ... the signal in the sensor, ...
Medicine Products: